Fulgent Genetics, Inc. provided earnings guidance for the year 2024. For the year, The company expects total core revenues to be approximately $280 million for 2024, representing a core growth of 7% year-over-year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.87 USD | +2.87% | +9.30% | -24.35% |
Jul. 01 | Fulgent Genetics, Inc.(NasdaqGM:FLGT) dropped from Russell 2000 Value-Defensive Index | CI |
Jul. 01 | Fulgent Genetics, Inc.(NasdaqGM:FLGT) dropped from Russell 2000 Defensive Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.35% | 636M | |
-18.17% | 8.55B | |
+87.40% | 4.63B | |
+16.31% | 2.98B | |
-3.15% | 2.65B | |
-2.10% | 1.89B | |
-53.27% | 1.81B | |
-12.97% | 1.56B | |
+21.59% | 1.27B | |
-47.96% | 1.07B |
- Stock Market
- Equities
- FLGT Stock
- News Fulgent Genetics, Inc.
- Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024